Stock 6855 ASCENTAGE PHARMA GROUP INTERNATIONAL
Add to a list
To use this feature you must be a member
Log inSign up

Ascentage Pharma Group International Stock

Equities

6855

KYG0519B1023

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:05 2024-06-07 am EDT 		5-day change 1st Jan Change
20.8 HKD +5.69% Intraday chart for Ascentage Pharma Group International +16.85% -23.81%
Jun. 05 Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% CI
Jun. 05 Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM CI

Financials

Sales 2024 * 300M 41.38M 323M Sales 2025 * 528M 72.92M 570M Capitalization 5.49B 758M 5.92B
Net income 2024 * -809M -112M -872M Net income 2025 * -620M -85.55M -668M EV / Sales 2024 * 18.3 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 10.4 x
P/E ratio 2024 *
-6.73 x
P/E ratio 2025 *
-8.87 x
Employees 583
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.36%
More Fundamentals * Assessed data

Chart Ascentage Pharma Group International

Dynamic Chart

Latest news about Ascentage Pharma Group International

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% CI
Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM CI
Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC CI
Ascentage Pharma to Present Four Studies on Anti-Cancer Drugs at US Oncology Meet; Shares Fall 4% MT
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting CI
Ascentage Pharma to Present Four Studies at US Oncology Meet MT
Ascentage Pharma Chairman Boosts Stake in Firm MT
Ascentage Pharma Group Directors Acquire Company Shares MT
Ascentage Pharma Widens Loss by Nearly 5% in 2023 MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet MT
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting CI
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3% MT
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia CI
Ascentage Pharma Trustee Buys 100,000 Shares MT
More news

Analyst Recommendations on Ascentage Pharma Group International

Ascentage Pharma Chairman Boosts Stake in Firm MT
Ascentage Pharma Group Directors Acquire Company Shares MT
More recommendations

Press releases Ascentage Pharma Group International

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress PR
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) AQ
Ascentage Pharma Announces 2023 Annual Results AQ
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA PR
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference PR
More press releases

Quotes and Performance

1 day+5.69%
1 week+16.85%
Current month+16.85%
1 month+7.66%
3 months-9.96%
6 months-14.75%
Current year-23.81%
More quotes

Highs and lows

1 week
17.30
Extreme 17.3
20.85
1 month
16.94
Extreme 16.94
21.65
Current year
15.42
Extreme 15.42
28.00
1 year
15.42
Extreme 15.42
28.15
3 years
11.16
Extreme 11.16
58.20
5 years
11.16
Extreme 11.16
58.20
10 years
11.16
Extreme 11.16
58.20
More quotes

Managers and Directors - Ascentage Pharma Group International

Managers TitleAgeSince
Da Jan Yang CEO
 Chief Executive Officer 61 09-04-30
Ming Guo FOU
 Founder 67 09-04-30
Yi Qing Chen DFI
 Director of Finance/CFO 40 21-11-28
Members of the board TitleAgeSince
David Sidransky BRD
 Director/Board Member 64 21-03-30
Shao Meng Wang BRD
 Director/Board Member 60 17-11-16
Zheng Yin BRD
 Director/Board Member 52 19-06-12
More insiders

ETFs positioned on Ascentage Pharma Group International

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.84% 4 M€ -27.92%
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.01% 114 M€ +4.36% -
More ETFs positioned on Ascentage Pharma Group International

Quotes

Date Price Change Volume
24-06-07 20.8 +5.69% 1,354,639
24-06-06 19.68 -1.50% 1,022,500
24-06-05 19.98 +4.94% 2,023,800
24-06-04 19.04 +7.33% 1,329,800
24-06-03 17.74 -0.34% 788,800

Delayed Quote Hong Kong S.E., June 07, 2024 at 04:09 am EDT

More quotes

Company Profile

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
Sector
Biotechnology & Medical Research
Calendar
2024-08-19 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Ascentage Pharma Group International

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.3 CNY
Average target price
27.24 CNY
Spread / Average Target
+41.18%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASCENTAGE PHARMA GROUP INTERNATIONAL Stock Ascentage Pharma Group International
-23.81% 758M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.21B
ARGENX SE Stock argenx SE
+3.23% 22.78B
GENMAB A/S Stock Genmab A/S
-10.44% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6855 Stock